Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.

As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up from $408.Maximize Your Portfolio with Data ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating ...

A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous ...

After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

CRISPR Therapeutics and Vertex Pharmaceuticals ... the keys to navigating this complex but rewarding sector. 3 Source: Ben Fidler, "Three biotechs raise $700M in Rare burst of IPO activity ...